secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0000947871-26-000034
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific to acquire Penumbra for ~$14.5B enterprise value ($374/share)
-------------------------------------------------------------------------------

- Deal consideration: ~73% cash, ~27% stock; $374 per Penumbra share; enterprise value ~$14.5B.
- Penumbra Q4 2025 revenue growth 21.4-22.0%; FY2025 revenue ~$1.4B (+17.3-17.5% YoY).
- Transaction expected to close in 2026; subject to Penumbra stockholder approval and customary conditions.
- First full year adj. EPS dilutive $0.06-0.08; neutral to slightly accretive in year two.
- Expands Boston Scientific into mechanical thrombectomy and neurovascular adjacencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/0000947871-26-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000094787126000034/ss5822817_8k.htm
  HTML page:      https://secwatch.observer/filing/0000947871-26-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer